Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A rare TMEM175 mutation drives Parkinson’s disease pathology by disrupting proton gating and lysosomal acidification
Xiaotong Yang, Ping Li, Man Lv, Lingyong Wang, Ruyi Shan, Zikai Jiang, Danzhen Chen, Fangqian Huang, Weijie Cai, Liding Zhao, Zuoyou Guo, Xinhui Chen, Zhidong Cen, Yichang Wang, Wei Yang, Xinran Li, Wei Luo, Lin Yang, Meiqin Hu, Haoxing Xu
Xiaotong Yang, Ping Li, Man Lv, Lingyong Wang, Ruyi Shan, Zikai Jiang, Danzhen Chen, Fangqian Huang, Weijie Cai, Liding Zhao, Zuoyou Guo, Xinhui Chen, Zhidong Cen, Yichang Wang, Wei Yang, Xinran Li, Wei Luo, Lin Yang, Meiqin Hu, Haoxing Xu
View: Text | PDF
Research Article Aging Cell biology Development

A rare TMEM175 mutation drives Parkinson’s disease pathology by disrupting proton gating and lysosomal acidification

  • Text
  • PDF
Abstract

Transmembrane protein 175 (TMEM175), implicated in Parkinson’s disease (PD) risk, has been variably proposed to function as a background K+ “leak” channel or a proton-activated proton channel in lysosomes. Here, we identified the rare TMEM175 variant p.L275R in a patient with early onset PD. Electrophysiological analyses revealed that TMEM175-L275R mutant proteins retain normal lysosomal expression and K+ “leak” activity, but specifically lose proton- and agonist-dependent activation gating. In skin fibroblasts isolated from the patient with PD harboring the monoallelic p.L275R mutation (TMEM175+/L275R), and in derived induced pluripotent stem cells and induced dopaminergic neurons, lysosomal H+ flux, acidification, and degradation were impaired. These lysosomal defects were corrected upon genome editing to produce the isogenic WT allele (+/+Cor), but appeared when the mutant allele was introduced onto a WT background (+/L275RMut). Pathological α-synuclein aggregation was facilitated in patient-derived (+/L275R) and mutation-introduced (+/L275RMut) neurons. Consistent with these genetic findings, pharmacological activation of TMEM175 with small-molecule agonists restored lysosomal functions and reduced α-synuclein aggregation in TMEM175+/L275R neurons. In in-vivo studies, equivalent-site–mutation knock-in mice demonstrated synucleinopathy and PD-like motor phenotypes. Collectively, our work provides genetic and pharmacological evidence that severe loss-of-function mutations may contribute causally to the onset age and pathogenesis of PD and identifies lysosomal proton channels and transporters as potential therapeutic targets for PD intervention.

Authors

Xiaotong Yang, Ping Li, Man Lv, Lingyong Wang, Ruyi Shan, Zikai Jiang, Danzhen Chen, Fangqian Huang, Weijie Cai, Liding Zhao, Zuoyou Guo, Xinhui Chen, Zhidong Cen, Yichang Wang, Wei Yang, Xinran Li, Wei Luo, Lin Yang, Meiqin Hu, Haoxing Xu

×

Figure 6

Lysosomal H+ currents, acidification, and hydrolytic degradation are compromised in primary neurons isolated from Tmem175L272R knock-in mice.

Options: View larger image (or click on image) Download as PowerPoint
Lysosomal H+ currents, acidification, and hydrolytic degradation are com...
(A) Genotypes of Tmem175+/+, Tmem175+/L272R, and Tmem175L272R/L272R mice. (B and C) Whole-LEL H+ currents in cultured mouse hippocampal neurons of the indicated genotypes in response to DCPIB (100 μM), with pHL = 4.6 and cytosolic pH (pHC) = 7.2. Genotyping results for Tmem175–/– mice are shown on the bottom right. Summary of current densities (at –120 mV) is shown in C; n = 5 (+/+); 4 (+/L272R); 3 (L272R/L272R); 5 (-/-) LELs. (D–F) Lysosomal acidity (Oregon Green dextran assay) and cathepsin B activity (MagicRed assay) in primary hippocampal neurons isolated from mice of indicated genotypes. Scale bar: 5 μm. Summaries are shown in E and F; n = 3 or 4 replicates. (G and H) Immunostaining of p-α-syn aggregation in primary neurons with the indicated genotypes after pff seeding for 7 days. β-tubulin III (β-tub III) served as the neuronal marker. Scale bar: 50 μm, n = 3 mice. (I and J) Western blots of p-α-syn aggregation in primary hippocampal neurons isolated from mice of indicated genotypes after pff seeding for 7 days. β-tub III served as the neuronal loading control. The thin black dividing line indicates splicing of noncontiguous lanes of the same blot. For panels H and J, results from separate experiments conducted with Tmem175–/– neurons are shown for comparison. Data are presented as means ± SEM, with dots representing biological replicates or indicated samples from ≥ 3 biological replicates. Statistical significance was determined using a 2-tailed Student’s t test for H and J and 1-way ANOVA test for C, E, and F, with ***P < 0.001, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts